A 1"4 kb fragment (nucleotides 2430 to 3901) encoding portions of the human parvovirus B19 structural proteins was inserted into the pRIT2 plasmid expression vector containing the gene encoding staphylococcal Protein A under the control of the phage 2 promoter PR. The fusion protein was used to raise antibodies in rabbits. The sera were shown by immune electron microscopy to agglutinate B19 particles and were also shown to recognize the VP2 B19 capsid protein, by Western blot analysis. The B19 antigenicity of the fusion protein was confirmed by immunoblot and enzyme immunoassay with IgG and IgM anti-B19-positive reference human sera.
The human parvovirus B19 was originally described by Cossart et al. (1975) . This virus was found to be involved in aplastic crises in patients with haemolytic diseases (Pattison et al., 1981) , due to B19's cytotoxic effect on the late erythroid progenitor cells (Mortimer et al., 1983; Young et al., 1984) . In children B19 is responsible for erythema infectiosum (fifth disease), a common epidemic disease (Anderson et al., 1984) . The outcome of infection in adults varies significantly; asymptomatic infection, febrile illness, purpura, pseudo-appendicitis and arthritis have been reported (Lefrere et al., 1985; Morinet et al., 1987; Reid et al., 1985; Shneerson et aL, 1980; White et al., 1985) . Transplacental infection of foetuses with B19 can cause spontaneous abortion and hydrops foetalis (Anand et al., 1987; Brown et al., 1984) . In immunosuppressed ' individuals, chronic infection can result in recurrent viraemia .
B19 viral particles contain a 5-4 kb linear ssDNA genome of either polarity with terminal palindromic sequences of 330 nucleotides (Clewley, 1984; Cotmore & Tattersall, 1984; Summers et al., 1983) . Most of the nucleotide sequences of two isolates have been determined (Blundell et al., 1987; Shade et al., 1986) . The organization of the B19 genome is similar to that of other parvoviruses: the structural or capsid proteins are encoded by the right half and the nonstructural proteins by the left half of the genome . In contrast the transcription pattern differs significantly when compared to other parvoviruses .
Nine specific B 19 transcripts have been identified in RNA extracted from infected cells; they all start at a single left-side promoter located at map unit 6. Four of the nine transcripts, designated a, a', c and d are 3.15, 3.03, 2-29 and 2.18 kb in length, respectively . These four mRNAs appear to encode the 84K VP1 (minor) and the 58K VP2 (major) structural proteins. The major non-structural protein (NS-1) of 77 K is encoded by an mRNA molecule of 2-31 kb . The function of the remaining four transcripts is not known.
Propagation of the virus has been accomplished only in primary cultures of human bone marrow cells (Ozawa et al., 1986) . Because B19 cannot be produced in sufficient quantities in cell cultures the major source of B19 is from viraemic sera from patients with the acute illness. In searching for a more convenient source of viral antigen for use in diagnostic tests, we have expressed a fragment of the B 19 genome as a fused protein with staphylococcal Protein A. The fusion protein expressed from vector pRIT2 in Escherichia coli was purified in a one-step procedure by IgG affinity chromatography. The hybrid protein produced was shown to be antigenic and to react with IgM and IgG antibodies present in human sera from patients with acute or past BI9 infection. A 3.2 kb HindlII-BamHI B19 DNA fragment isolated directly from a viraemic serum sample (Desm) was cloned into pBR322 as previously reported (Morinet et al., 1986) . From this plasmid a 1.4 kb HindlII-BamHI fragment corresponding to nucleotides 2430 to 3901 and encoding the part common to VP1 and VP2 proteins was subcloned into M13mp8 and propagated in TG1 cells. Partial DNA sequencing was performed by using a universal primer and the dideoxynucleotide termination method of Sanger et al. (1977) . Our sequencing data were in full agreement with those reported by Shade et al. (1986) . Site-specific in vitro mutagenesis was performed to eliminate an in-frame stop codon located 5' to the VP1/VP2 initiator and to create an EcoRI cloning site. The single-stranded template (128 ng) and the 28-mer oligonucleotide (20 ng) were annealed by heating at 60 °C for 30 min and then freezing at -20 °C for 15 min. To the annealing mixture 3 mmol of each of the four dNTPs, 400 units (U) of T4 DNA ligase and 5 U of the DNA polymerase I Klenow fragment were added. After 1 h at room temperature, the solution was treated with phenol-chloroform and DNA precipitated with ethanol. The closed circular DNA was used to transform TG1 cells. DNA from transformants was analysed by sequencing to ascertain that in vitro mutagenesis had occurred. The mutant 1-4 kb EcoRIBamHI fragment (4M B19) obtained was then cloned into the Protein A gene fusion vector pRIT2 (Pharmacia). In that vector, a portion of the 2 cro gene is fused to the IgG-binding domains of Protein A and supplies the ATG start codon; genes inserted into the multiple cloning site are fused to the IgG-binding domains and are expressed from the right promoter (PR) (Nilsson et al., 1985) . E. coli strain NFIB with the CI857 repressor was transformed according to Morrison (1979) ; transformants were analysed by the method of Holmes & Quigley (1981) .
Expression of the protein under control of the PR promoter was done essentially as described by Zabeau & Stanley (1982) . The cells were grown at 30 °C to an optical density at 500 nm (OD550) of 0.1 and shifted to 42 °C by mixing with an equal volume of broth heated to 54 °C. The culture was incubated at 42 °C for 30 min; cells were sonicated (4 x 30 s, MSE sonicator) in phosphate-buffered saline (PBS) containing 0.05 % Tween and 2 mM-PMSF. The cell debris was pelleted (by centrifugation at 2000 g for 30 min at 4 °C) and the supernatant was rocked with 1/10 the volume of human IgG-Sepharose (Pharmacia) at room temperature for 2 h. Efficient elution of fused proteins was performed at 10 ml/h with 2 bed volumes of 500 mM-acetic acid, pH 3-4. Samples before and after purification through the column were analysed by 12% SDS-PAGE in gels stained with Coomassie Brilliant Blue (Fig. 1 a) . After column purification, the clone containing the B19 insert expressed additional polypeptides that were larger than the Protein A moiety alone (i.e. were fusion proteins). The polyacrylamide gel was blotted onto nitrocellulose (Western blot) which was incubated with peroxidase-labelled rabbit IgG (Fig.  1 b) , confirming the presence of hybrid proteins. Since the Mr of the Protein A moiety encoded by this plasmid is 30K, the estimated intact fusion protein should be 80K. This full-size fused protein is present in only minute amounts (Fig. la, b) whereas a series of intermediate-size products with a major polypeptide of 67 K are observed. These are probably either breakdown or prematurely terminated products of the fusion protein. Detection and quantification of fusion proteins was performed by an ELISA. Human IgG (100 t11) (Centre National de Transfusion Sanguine, Paris, France) at a concentration of 1 ~tg/ml in PBS was used to coat microplate wells (Falcon III, Becton-Dickinson) by overnight incubation at 4 °C. Serial 1 in 10 dilutions of cell extract were added. After 2 h at room temperature, free IgG-binding sites were titrated by adding peroxidase-linked Protein A (Miles Laboratories) for 1 h at room temperature. By using pure Protein A (Miles Laboratories) as a standard a yield of 300 ~tg per 200 ml culture could be estimated (induction OD550 = 0.1). Two New Zealand white rabbits were immunized at 10 subcutaneous sites with 30 ~tg per rabbit of the fusion protein emulsified in complete Freund's adjuvant. Two booster injections using the same amount of protein in complete and incomplete Freund's adjuvant were used 3 and 6 weeks later. Preimmune as well as immune rabbit sera were tested. Only the immune rabbit sera agglutinated B19 particles, as observed by immune electron microscopy (data not shown). Moreover, immune rabbit sera reacted strongly with the VP2 shown by Western blot analysis; VP2 was obtained after centrifuging B 19 virus through a 20 sucrose cushion (Fig. 2) . These results allow us to conclude that the fusion protein has the antigenicity of B19 structural protein.
The use of the B 19-Protein A hybrid protein as a diagnostic tool to detect B 19 IgG antibodies in human sera from infected patients was evaluated by Western blot analysis. As shown in Fig.  3 , serum samples reacted specifically with the fusion protein after the blocking of the Protein A moiety by 10~ normal rabbit serum (Dako). However because of the presence of numerous breakdown products of the fused protein, this approach is not suitable for diagnostic purposes. The presence of IgM reactive with the B19 fusion protein was analysed by an ELISA in 46 reference human sera (14 negative and 32 positive by radioimmunocapture assay, RIA). Microtitre plates (Falcon microtest III, Becton-Dickinson) were coated with B 19 fusion protein (37 ng per well under 100 pl 50 mu-carbonate buffer pH 9.6) and incubated overnight at 4 °C. After blocking with 6~o bovine serum albumin in carbonate buffer (18 h, 4 °C) and washing (20 raM-Tris-500 mM-NaC1 pH 7-4, 0-1 ~ Tween 20), 100 ~tl of 100-fold diluted sera (100 mMsodium citrate buffer pH 5-6 containing 10~ foetal calf serum and 10~ glycerol) were added and incubated at 40 °C for 30 min. All sera were preabsorbed with anti-human IgG (absorbent RF, Behring) to eliminate the rheumatoid faction (RF). After washing, 100 I~1 of peroxidaseconjugated anti-human IgM (1000-fold dilution in washing solution, Nordic Pharmaceutical) were added. After 30 min at 40°C, plates were washed and incubated with 100 pl of Fig. 3 . Western blot analysis of the fusion protein after separation by 12% SDS-PAGE followed by blotting onto nitrocellulose membrane. The Protein A moiety was blocked with 10~o normal rabbit serum. Antibodies and the peroxidase-labeUed conjugate were used respectively at 100-fold and 1000-fold dilutions. Lane 1, B19 IgG-negative reference human serum; lanes 2, 3, 4 and 5, B19 IgG-positive reference human sera. Lanes 6, 7 and 8, immune rabbit sera. Mr values are indicated.
orthophenylene diamine [10 mg/ml of H202,0.03 ~ sodium citrate (50 mM, pH 5.6)] for 20 min at room temperature in the dark. The reaction was stopped with 100 Ixl of 2 M-H2SO4 and the absorbance was measured at 492 nm (Titertek Multiskan, Flow Laboratories). If the base line value (BLV) was taken to be 1 with a positive to negative (P/N) ratio > 2, only 26 out of the 32 RIA-positive sera were also positive; the remaining six and the 14 RIA-negative sera are negative by ELISA. If the BLV was 0.8 (P/N = 1.6), 29 of 32 RIA-positive sera and three of 14 IgM B19-negative sera are positive by the ELISA. The ELISA is rapid, easy to perform (two steps) and does not use B19 virus as an antigen. It is at present possible to detect specific IgM only during the acute phase of B 19 infection; low viral titres cannot be tested due to the requirement for a high BLV in order to assure high specificity. A large panel of sera is under investigation to assess this ELISA for IgG detection in epidemiological studies.
From these results we can conclude that the B19-Protein A fusion protein could provide an amenable source of viral B19 antigen. Cotmore et al. (1986) have described the construction of two expression plasmids containing B 19 viral DNA sequences encoding the non-structural and capsid proteins of the viral genome. The rabbit antisera directed against the hybrid protein sequence encoded between nucleotides 2897 and 3749 recognized both the 83 K and 58 K capsid polypeptides in plasma from acutely infected patients; however it was not demonstrated that the product could be used as a source of antigen in routine immunological tests. Recently, Sisk & Berman (1987) have produced a fl-galactosidase-B 19 structural protein fusion product in E. coli but they did not analyse the antigenicity of the recombinant protein by ELISA. Furthermore the binding of specific IgM to their B19 fusion protein was not mentioned.
Further studies are in progress to improve the ELISA antibody procedure by developing an IgM immunocapture test.
